PlantForm Corporation

We're pleased to announce that PlantForm Corporation and Bio-Manguinhos/Fiocruz have signed a new agreement to develop a pembrolizumab cancer drug and up to 5 future products for the Brazilian and other world markets.

Pembrolizumab is widely used alone or in combination with other drugs to treat a variety of cancers including certain types of breast cancer, skin cancer (including melanoma), non-small cell lung cancer and more than a dozen other types.

Read the full press release:

PlantForm, Bio-Manguinhos/Fiocruz sign new agreement to develop biosimilar pembrolizumab cancer drug and additional products GUELPH, Ont., CANADA, March 7, 2023 — Canadian biopharmaceutical innovator PlantForm Corporation and Bio-Manguinhos / Fiocruz (Health Ministry of Brazil) have signed a collaborative research and development agreement to develop a biosimilar pembrolizumab and up to five future products for the Braz...

Our thanks to the Grand River Agricultural Society for supporting our travel to 2022 to discuss regional and global partnering opportunities for PlantForm’s animal health programs.

PlantForm's animal health solutions include the world’s first plant-based vaccine for Classical Swine Fever and an edible antibody that prevents E.coli infection in pigs.